Is Hepatitis C Type 3 a difficult type to treat?

Hepatitis C mainly refers to the infection of the hepatitis C virus in the patient's liver. Compared with hepatitis B, hepatitis C has a longer incubation period in the human body, so hepatitis C is also difficult to detect and treat in a timely manner. When you go to the hospital to check for hepatitis C, there are many different types of biscuits, which are mainly differentiated according to the severity of hepatitis C. And if a patient has hepatitis C type 3, is it difficult to treat?

The hepatitis C virus is extremely hidden, with a latent period of up to decades, so the rate of missed diagnosis among patients is extremely high. Many patients are not discovered until they develop cirrhosis or even liver cancer. The current standard treatment for chronic hepatitis C in my country is long-acting interferon + ribavirin. Scientists at the U.S. Food and Drug Administration (FDA) have released a new report explaining why the indication for the hepatitis C virus (HCV) treatment Vosevi is restricted by genotype.

To date, an estimated 1.5 million patients worldwide have been prescribed sofosbuvir-based HCV treatment regimens. Gilead has launched four HCV treatment options since 2013. The FDA approved Gilead in July 2017. Gilead is used to treat adult patients with chronic hepatitis C virus (HCV) genotypes 1-6 infection without cirrhosis or with mild cirrhosis. Gilead is a combination tablet containing three fixed-dose ingredients: sofosbuvir, velpatasvir, and voxilaprevir.

For patients who have been previously treated with the direct-acting antiviral drug sofosbuvir or NS5A inhibitors, Gilead is the preferred treatment. However, if NS5A inhibitor-naive patients have taken sofosbuvir, Gilead Sciences is only suitable for patients with HCV genotype 1a or 3. In the POLARIS-4 study, patients were randomized to receive either Epclusa or Epclusa. The 12-week SVR rate was higher with Epclusa for patients with HCV genotype 1a (98% vs. 89%) and genotype 3 (96% vs. 85%). However, there was no significant difference in the 12-week SVR rates between the two treatment regimens in patients with genotypes 1b and 2. There are insufficient data to determine whether responses differ among patients with HCV genotypes 4, 5, and 6. In fact, the most suitable drug for treating hepatitis C is still Epclusa, because Epclusa can treat all types of hepatitis C, and the treatment effect is also very good.